Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.

Revenue
+14.5%
EPS
−43.6%
Free cash flow
+28.9%
Total debt
+142.7%

Quarter to September 2026, against a year earlier

110.08 3.52 −3.10%
Market cap
$196.6B
P/E
42.3×
Fwd P/E
35.1×
Dividend yield
2.22%
F-score
5/9
Altman Z
5.61
Beneish M
−2.50
Dividend safety
62/100

Abbott Laboratories (ABT) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Abbott Laboratories (ABT) trades at a EV/FCF of 28.7×. Over the past ten years it has ranged from 20.3× (October 2022) to 47.2× (November 2020); the current reading is higher than 37% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 30.0× (6.01%)
FY2024 32.0× (18.57%)
FY2023 39.2× 54.14%
FY2022 25.5× (14.53%)
FY2021 29.8× (17.03%)
FY2020 35.9× (3.51%)
FY2019 37.2× 28.16%
FY2018 29.0× 6.94%
FY2017 27.1× (5.14%)
FY2016 28.6× (20.64%)

Quarterly newest first

Period EV/FCF Change
Sep 2026 25.4× 7.61%
Jun 2026 23.6× (15.20%)
Mar 2026 27.9× (7.20%)
Dec 2025 30.0× (12.91%)
43 more quarters

Against its own ten years

Low 20.3× High 47.2×
Ten-year median 31.5×
Current reading's percentile 36

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on ABT